Table 3. Performance of published gene signatures.
Signature | Endpoint | Stage | Datasets | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Blaveri (6) | Kim (13) | Lindgren (9) | Sanchez-Carbayo (7) | Riester | ||||||||
P | C | P | C | P | C | P | C | P | C | |||
Blaveri (6) | OS | MI | 0.01 | 0.66 | 0.66 | 0.57 | 0.15 | 0.60 | 0.66 | 0.61 | 0.73 | 0.56 |
Kim (13) | OS | MI | 0.41 | 0.60 | 0.00 | 0.75 | 0.76 | 0.53 | 0.40 | 0.54 | 0.84 | 0.50 |
Kim (13) | DSS | MI | 0.11 | 0.57 | 0.00 | 0.72 | 0.84 | 0.63 | 0.26 | 0.60 | 0.87 | 0.56 |
Kim (13) | Progression | non-MI | 0.70 | 0.50 | 0.09 | 0.56 | 0.53 | 0.53 | 0.04 | 0.59 | 0.27 | 0.56 |
Lindgren (9) | OS | all | 0.29 | 0.55 | 0.17 | 0.55 | 0.10 | 0.72 | 0.48 | 0.50 | 0.93 | 0.54 |
Sanchez-Carbayo (7) | OS | MI | 0.15 | 0.56 | 0.56 | 0.54 | 0.33 | 0.50 | 0.02 | 0.60 | 0.39 | 0.50 |
Sanchez-Carbayo (7) | Progression | MI | 0.21 | 0.50 | 0.02 | 0.58 | 0.42 | 0.73 | 0.15 | 0.51 | 0.95 | 0.54 |
Smith (14) | Progression | MI | 0.42 | 0.54 | 0.17 | 0.54 | 0.15 | 0.58 | 0.15 | 0.60 | 0.79 | 0.50 |
Riester | OS | MI | 0.04 | 0.76 | 0.04 | 0.75 | 0.002 | 0.87 | 0.005 | 0.74 | 0.06 | 0.71 |
P = p-value; C = C-statistic; OS = overall survival; DSS = disease-specific survival, MI=muscle-invasive